Factors for the development of anemia in patients with newly introduced olaparib: A retrospective case-control study.

Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE

Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins

Folic Acid Deficiency*/complications ; Anemia*/chemically induced ; Anemia*/epidemiology ; Anemia*/complications ; Vitamin B 12 Deficiency*/complications; Humans ; Case-Control Studies ; Retrospective Studies ; Carboplatin ; Dysgeusia ; Hemoglobins/analysis ; Folic Acid/therapeutic use ; Vitamin B 12/therapeutic use

Anemia is the most common dose-limiting toxicity of olaparib. However, few studies have analyzed the clinical features of olaparib-induced anemia. This study investigated the clinical features of olaparib-induced anemia. Additionally, the role of folate or vitamin B12 in olaparib-induced anemia was examined. This retrospective case-control study included patients who received olaparib at Mie University Hospital between January 2018 and December 2020. Data were collected between initiation of olaparib and discontinuation of olaparib or till December 2021. We investigated the development of grade ≥ 3 anemia during olaparib administration for at least 1 year. We examined patients with grade ≥ 3 anemia considering the mean corpuscular volume (MCV), its association with gastrointestinal events and cumulative dose of carboplatin. For the sub-study analysis, data on patients treated with olaparib for ovarian or endometrial cancer were collected to evaluate the Common Terminology Criteria for Adverse Events (CTCAE) or monthly changes in folate or vitamin B12 levels from baseline to 3 months after olaparib initiation. These data were collected between initiation of olaparib and discontinuation of olaparib or till November 2022. Patients with no data on folic acid or vitamin B12 levels were excluded from the sub-study. In the main study, 40 patients were included. Eighteen patients (45%) developed grade ≥ 3 anemia, and all patients discontinued treatment (94%) or reduced olaparib dose (67%) after developing anemia. Among the patients with grade ≥ 3 anemia, 9 (50%) exhibited macrocytic anemia and 15 (83%) had previously received carboplatin. The incidence of grade ≥ 2 dysgeusia was significantly higher in patients with grade ≥ 3 anemia (P = .034). Moreover, the cumulative dose of previously administered carboplatin was higher in patients who had 3 episodes of anemia (P = .102). In sub-study, 12 had data on folic acid and vitamin B12 levels. Sub-study analysis showed that none fulfilled the criteria for deficiency of folate or vitamin B12, while 3 developed grade 3 anemia. This study revealed that olaparib-induced anemia frequently occurs as macrocytic and normocytic erythroblastic anemia without folate or vitamin B12 deficiencies. A high cumulative dose of previously administered carboplatin and dysgeusia may be associated with olaparib-induced anemia.
Competing Interests: The authors have no funding and conflicts of interest to disclose.
(Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)

U.S. Food and Drug Administration. Astra-Zeneca LYNPARZA Prescribing Information. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208558s000lbl.pdf [access date November 5, 2018].
Herceg Z, Wang ZQ. Functions of poly (ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res. 2001;477:97–110.
Sousa FG, Matuo R, Soares DG, et al. PARPs and the DNA damage response. Carcinogenesis. 2012;33:1433–40.
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.
Wu L, Zhu J, Yin R, et al. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecol Oncol. 2021;160:175–81.
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616–34.
Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020;136:801–13.
Madeddu C, Neri M, Sanna E, et al. Experimental drugs for chemotherapy- and cancer-related anemia. J Exp Pharmacol. 2021;13:593–611.
Gao F, Cheng K, Zhao F, et al. Prevalence and characteristics of anemia in patients with solid cancers at diagnosis in southwest China. Asian Pac J Cancer Prev. 2011;12:2825–8.
Shammo JM, Usha L, Richardson KJ, et al. Olaparib-induced severe folate deficiency in a patient with advanced ovarian cancer. J Oncol Pract. 2019;15:405–7.
Yohannan B, McIntyre K, Feldman M. Severe folate deficiency anemia associated with the use of a PARP inhibitor (olaparib) in a patient with fallopian tube cancer. Case reports in Internal medicine. 2019;6:1.
Reynolds EH. Schizophrenia-like psychoses of epilepsy and disturbances of folate and vitamin B12 metabolism induced by anticonvulsant drugs. Br J Psychiatry. 1967;113:911–9.
Logan EC, Williamson LM, Ryrie DR. Sulphasalazine associated pancytopenia may be caused by acute folate deficiency. Gut. 1982;27:868–72.
Rooney PJ, Housley E. Trimethoprim-solphamethoxazole in folic acid deficiency. Br Med J. 1972;2:656.
Langan RC, Goodbred AJ. Vitamin B12 deficiency: recognition and management. Am Fam Physician. 2017;96:384–9.
Polasek TM, Lin FP, Miners JO, et al. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome p450 activity: a criteria-based assessment. Br J Clin Pharmacol. 2011;71:727–36.
Pilla Reddy V, Bui K, Scarfe G, et al. Physiologically based pharmacokinetic modeling for olaparib dosing recommendations: bridging formulations, drug interactions, and patient populations. Clin Pharmacol Ther. 2019;105:229–41.
Ohgami N, Kondo T, Kato M. Effects of light smoking on extra-high-frequency auditory thresholds in young adults. Toxicol Ind Health. 2011;27:143–7.
Michels WM, Grootendorst DC, Verduijn M, et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5:1003–9.
Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
National Cancer Institute. Common Terminology Criteria for Adverse Events (version 5.0). 2017. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm [access date April 30, 2020].
Buttarello M. Laboratory diagnosis of anemia: are the old and new red cell parameters useful in classification and treatment, how? Int J Lab Hematol. 2016;38(Suppl 1):123–32.
Valabrega G, Scotto G, Tuninetti V, et al. Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy. Int J Mol Sci. 2021;22:4203.
Farrés J, Martín-Caballero J, Martínez C, et al. Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice. Blood. 2013;122:44–54.
Farrés J, Llacuna L, Martin-Caballero J, et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ. 2015;22:1144–57.
Ruiz-Schutz VC, Gomes LM, Mariano RC, et al. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2019;141:163–73.
Li N, Zhou H, Tang Q. Red blood cell distribution width: a novel predictive indicator for cardiovascular and cerebrovascular diseases. Dis Markers. 2017;2017:7089493.
Visentin M, Diop-Bove N, Zhao R, et al. The intestinal absorption of folates. Annu Rev Physiol. 2014;76:251–74.
Urquhart BL, Gregor JC, Chande N, et al. The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. Am J Physiol Gastrointest Liver Physiol. 2010;298:248–54.
Hossain MB, Ji P, Anish R, et al. Poly (ADP-ribose) polymerase 1 interacts with nuclear respiratory factor 1 (NRF-1) and plays a role in NRF-1 transcriptional regulation. J Biol Chem. 2009;284:8621–32.
Gonzalez-Velez M, Mead-Harvey C, Kosiorek HE, et al. Racial/ethnic differences in patients with anemia and folate deficiency. Int J Lab Hematol. 2020;42:403–10.
Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244–50.
Ponticelli E, Clari M, Frigerio S, et al. Dysgeusia and health-related quality of life of cancer patients receiving chemotherapy: a cross-sectional study. Eur J Cancer Care (Engl). 2017;26:e12633.
Baranwal A, Baranwal A, Roy N. Association of household environment and prevalence of anemia among children under-5 in India. Front Public Health. 2014;2:196.
Leifert JA. Anaemia and cigarette smoking. Int J Lab Hematol. 2008;30:177–84.
Sæbø G, Kvaavik E. Accumulation of material and lifestyle problems among daily smokers in Norway 1999 to 2013 - a cross-sectional analysis. BMC Public Health. 2016;16:781.
Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–99.
Tashiro R, Kawazoe H, Mamishin K, et al. Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: a multicenter retrospective study. Front Oncol. 2022;12:898150.
García-de-Teresa B, Rodríguez A, Frias S. Chromosome instability in fanconi anemia: from breaks to phenotypic consequences. Genes (Basel). 2020;11:1528.
Renaudin X, Rosselli F. The FANC/BRCA pathway releases replication blockades by eliminating DNA interstrand cross-links. Genes (Basel). 2020;11:585.
Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010;116:4578–87.
Basourakos SP, Li L, Aparicio AM, et al. Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions. Curr Med Chem. 2017;24:1586–606.
Chen WW, Wang F, Xu RH. Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis. PLoS One. 2013;8:e68974.
Zhang Y, Zheng J, Jiang Y, et al. Neglected, drug-induced platinum accumulation causes immune toxicity. Front Pharmacol. 2020;11:1166.
Zhang Y, Huang X, Feng S, et al. Platinum accumulation and cancer-related fatigue, correlation with IL-8, TNF-α and hemocytes. Front Pharmacol. 2021;12:658792.
Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187–95.
Tan DS, Rothermundt C, Thomas K, et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26:5530–6.

WOH1JD9AR8 (olaparib)
BG3F62OND5 (Carboplatin)
0 (Hemoglobins)
935E97BOY8 (Folic Acid)
P6YC3EG204 (Vitamin B 12)

Date Created: 20230728 Date Completed: 20230731 Latest Revision: 20240911

20240912

PMC10378826

10.1097/MD.0000000000034123

37505180